Galectin Therapeutics Inc. - Common Stock (GALT)

4.0800
+0.00 (0.00%)
NASDAQ · Last Trade: Dec 30th, 5:38 PM EST
QuoteNewsPress ReleasesChartHistoricalFAQAboutCompetitors
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of - GALT
NEW YORK, Dec. 30, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Galectin Therapeutics Inc. (“Galectin” or the “Company”) (NASDAQ: GALT).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
By Pomerantz LLP · Via GlobeNewswire · December 30, 2025
GALT Investors Have Opportunity to Join Galectin Therapeutics Inc. Fraud Investigation with The Schall Law Firm
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Galectin Therapeutics Inc. (“Galectin” or “the Company”) (NASDAQ: GALT) for violations of the securities laws.
By The Schall Law Firm · Via Business Wire · December 29, 2025
Cancer Rates Are Surging in Young Adults — Here’s Where the Smart Money Is Going
Issued on behalf of Oncolytics Biotech Inc.   Vancouver, BC – June 18, 2025 – USA News Group News Commentary – According to a recent report in Newsweek, more Americans younger than 50 are getting cancer. In fact, the report cites a recent study from the National Institutes of Health (NIH), which found that between […]
Via FinancialNewsMedia · June 18, 2025